Literature DB >> 17705170

Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load <50 copies/ml.

Bernd Kupfer1, Bertfried Matz, Martin P Däumer, Fabienne Roden, Jürgen K Rockstroh, Nazifa Qurishi, Ulrich Spengler, Rolf Kaiser.   

Abstract

Despite prolonged undetectable plasma viral load some HIV-1 infected patients have been reported to develop resistance-associated mutations leading to treatment failure. The mechanisms for this phenomenon and the point of origin for residual viral evolution are still not elucidated. In order to quantify cell-associated HIV-1 RNA in patients with different levels of plasma viremia paired cell-associated HIV-1 RNA loads and plasma viral loads were determined. Weak inverse correlation between these parameters and the amounts of CD4(+) T cells was observed, whereas there was no correlation between viral loads and CD8(+) T cells or CD14(+) monocytes, respectively. In a subset of patients, cell-associated and plasma HIV-1 env V3 sequences were analyzed. Plasma viral load and the amount of cell-associated HIV-RNA correlated strongly. However, in 62.3% of patients with undetectable plasma viral load cell-associated HIV-RNA could be detected. Analyses of HIV-RNA in plasma and blood cells showed identical sequences in 4/19 patients, whereas the majority of patients had differing HIV-1 RNA sequences in plasma and cells, respectively. In summary, this study shows that residual viral replication in peripheral blood still occurs in the majority of patients with undetectable plasma viral load. Since these replication events could lead to ongoing viral evolution it should be considered to optimize antiretroviral therapy in order to minimize the development of drug resistance. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17705170     DOI: 10.1002/jmv.20993

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  HIV load testing with small samples of whole blood.

Authors:  Katrin Steinmetzer; Thomas Seidel; Andreas Stallmach; Eugen Ermantraut
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

2.  Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test.

Authors:  Linda L Jagodzinski; Mark M Manak; Holly R Hack; Ying Liu; Jennifer A Malia; Joanna Freeman; Nittaya Phanuphak; Mark de Souza; Eugène D Kroon; Donn J Colby; Nitiya Chomchey; Michelle A Lally; Nelson L Michael; Jintanat Ananworanich; Sheila A Peel
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

Review 3.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

4.  Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy.

Authors:  Keith Shults; Leanne Flye-Blakemore; Bruce K Patterson; Tarek Elbeik
Journal:  Future Virol       Date:  2012-08       Impact factor: 1.831

5.  Development of a sensitive, quantitative assay with broad subtype specificity for detection of total HIV-1 nucleic acids in plasma and PBMC.

Authors:  C N Kibirige; M Manak; D King; B Abel; H Hack; D Wooding; Y Liu; N Fernandez; J Dalel; Steve Kaye; N Imami; L Jagodzinski; J Gilmour
Journal:  Sci Rep       Date:  2022-01-28       Impact factor: 4.996

6.  Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Authors:  Alexander O Pasternak; Suzanne Jurriaans; Margreet Bakker; Jan M Prins; Ben Berkhout; Vladimir V Lukashov
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

Review 7.  Cell-associated HIV RNA: a dynamic biomarker of viral persistence.

Authors:  Alexander O Pasternak; Vladimir V Lukashov; Ben Berkhout
Journal:  Retrovirology       Date:  2013-04-15       Impact factor: 4.602

8.  Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART.

Authors:  Steven Sanche; Thibault Mesplède; Nancy L Sheehan; Jun Li; Fahima Nekka
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.